Cargando…

EPEN-15. Radiotherapy with helium ions has the potential to improve both endocrine and neurocognitive outcome in pediatric patients with ependymoma

BACKGROUND: Ependymoma are the third most frequent pediatric brain tumors. To prevent local recurrence, the resection site should be irradiated. Especially the treatment of pediatric patients requires precise dose application and optimal protection of organs at risk. Compared to photon radiation tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Wickert, Ricarda, Adeberg, Sebastian, Deng, Maximilian, Tessonnier, Thomas, Hoeltgen, Line, Debus, Jürgen, Herfarth, Klaus, Harrabi, Semi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164851/
http://dx.doi.org/10.1093/neuonc/noac079.152
_version_ 1784720242127142912
author Wickert, Ricarda
Adeberg, Sebastian
Deng, Maximilian
Tessonnier, Thomas
Hoeltgen, Line
Debus, Jürgen
Herfarth, Klaus
Harrabi, Semi
author_facet Wickert, Ricarda
Adeberg, Sebastian
Deng, Maximilian
Tessonnier, Thomas
Hoeltgen, Line
Debus, Jürgen
Herfarth, Klaus
Harrabi, Semi
author_sort Wickert, Ricarda
collection PubMed
description BACKGROUND: Ependymoma are the third most frequent pediatric brain tumors. To prevent local recurrence, the resection site should be irradiated. Especially the treatment of pediatric patients requires precise dose application and optimal protection of organs at risk. Compared to photon radiation treatment, proton therapy often achieves better results regarding target coverage and organ-sparing. Due to their physical properties, helium ions can further reduce side effects, providing better protection of healthy tissue despite similar target coverage. PATIENTS AND METHODS: In our in-silico study, 15 pediatric patients (median age six years) with ependymoma located in the posterior cranial fossa were considered. All patients underwent adjuvant radiotherapeutic treatment with active scanned protons at Heidelberg Ion-Beam Therapy Center (HIT). Both helium ion and highly conformal IMRT plans were calculated to evaluate the potential dosimetric (and clinical) benefit of ion beam therapy compared to the current state of the art photon-based treatments. RESULTS: Target coverage was comparable in all three modalities (He, H(+), Ph): homogeneity indices (HI) and inhomogeneity coefficients (IC) of HI(He)=5.8±3.8, HI(H)(+)=7.5±4.0, HI(Ph)=6.4±4.3, IC(He)=0.2±0.1, IC(H+)=0.2±0.1, IC(Ph)=0.2±0.1. As expected, the integral dose absorbed by the healthy brain tissue could be reduced significantly using helium ions versus IMRT (-45.3%±15.1%). Based on our preliminary results, even compared to active scanned protons – currently the most precise radiation technique worldwide – the relative dose reduction for critical neuronal structures using helium ions on average amounts to -27.2%±14.4%. CONCLUSION: Previous studies could clearly demonstrate that the dosimetric advantage of protons translates into a measurable clinical benefit for pediatric patients with brain tumors. Given the dose response relationship of critical organs at risk, the results of our in-silico study provide a strong rationale that the use of helium ions has the potential to even further reduce the risk for treatment related sequelae.
format Online
Article
Text
id pubmed-9164851
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-91648512022-06-05 EPEN-15. Radiotherapy with helium ions has the potential to improve both endocrine and neurocognitive outcome in pediatric patients with ependymoma Wickert, Ricarda Adeberg, Sebastian Deng, Maximilian Tessonnier, Thomas Hoeltgen, Line Debus, Jürgen Herfarth, Klaus Harrabi, Semi Neuro Oncol Ependymoma BACKGROUND: Ependymoma are the third most frequent pediatric brain tumors. To prevent local recurrence, the resection site should be irradiated. Especially the treatment of pediatric patients requires precise dose application and optimal protection of organs at risk. Compared to photon radiation treatment, proton therapy often achieves better results regarding target coverage and organ-sparing. Due to their physical properties, helium ions can further reduce side effects, providing better protection of healthy tissue despite similar target coverage. PATIENTS AND METHODS: In our in-silico study, 15 pediatric patients (median age six years) with ependymoma located in the posterior cranial fossa were considered. All patients underwent adjuvant radiotherapeutic treatment with active scanned protons at Heidelberg Ion-Beam Therapy Center (HIT). Both helium ion and highly conformal IMRT plans were calculated to evaluate the potential dosimetric (and clinical) benefit of ion beam therapy compared to the current state of the art photon-based treatments. RESULTS: Target coverage was comparable in all three modalities (He, H(+), Ph): homogeneity indices (HI) and inhomogeneity coefficients (IC) of HI(He)=5.8±3.8, HI(H)(+)=7.5±4.0, HI(Ph)=6.4±4.3, IC(He)=0.2±0.1, IC(H+)=0.2±0.1, IC(Ph)=0.2±0.1. As expected, the integral dose absorbed by the healthy brain tissue could be reduced significantly using helium ions versus IMRT (-45.3%±15.1%). Based on our preliminary results, even compared to active scanned protons – currently the most precise radiation technique worldwide – the relative dose reduction for critical neuronal structures using helium ions on average amounts to -27.2%±14.4%. CONCLUSION: Previous studies could clearly demonstrate that the dosimetric advantage of protons translates into a measurable clinical benefit for pediatric patients with brain tumors. Given the dose response relationship of critical organs at risk, the results of our in-silico study provide a strong rationale that the use of helium ions has the potential to even further reduce the risk for treatment related sequelae. Oxford University Press 2022-06-03 /pmc/articles/PMC9164851/ http://dx.doi.org/10.1093/neuonc/noac079.152 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Ependymoma
Wickert, Ricarda
Adeberg, Sebastian
Deng, Maximilian
Tessonnier, Thomas
Hoeltgen, Line
Debus, Jürgen
Herfarth, Klaus
Harrabi, Semi
EPEN-15. Radiotherapy with helium ions has the potential to improve both endocrine and neurocognitive outcome in pediatric patients with ependymoma
title EPEN-15. Radiotherapy with helium ions has the potential to improve both endocrine and neurocognitive outcome in pediatric patients with ependymoma
title_full EPEN-15. Radiotherapy with helium ions has the potential to improve both endocrine and neurocognitive outcome in pediatric patients with ependymoma
title_fullStr EPEN-15. Radiotherapy with helium ions has the potential to improve both endocrine and neurocognitive outcome in pediatric patients with ependymoma
title_full_unstemmed EPEN-15. Radiotherapy with helium ions has the potential to improve both endocrine and neurocognitive outcome in pediatric patients with ependymoma
title_short EPEN-15. Radiotherapy with helium ions has the potential to improve both endocrine and neurocognitive outcome in pediatric patients with ependymoma
title_sort epen-15. radiotherapy with helium ions has the potential to improve both endocrine and neurocognitive outcome in pediatric patients with ependymoma
topic Ependymoma
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164851/
http://dx.doi.org/10.1093/neuonc/noac079.152
work_keys_str_mv AT wickertricarda epen15radiotherapywithheliumionshasthepotentialtoimprovebothendocrineandneurocognitiveoutcomeinpediatricpatientswithependymoma
AT adebergsebastian epen15radiotherapywithheliumionshasthepotentialtoimprovebothendocrineandneurocognitiveoutcomeinpediatricpatientswithependymoma
AT dengmaximilian epen15radiotherapywithheliumionshasthepotentialtoimprovebothendocrineandneurocognitiveoutcomeinpediatricpatientswithependymoma
AT tessonnierthomas epen15radiotherapywithheliumionshasthepotentialtoimprovebothendocrineandneurocognitiveoutcomeinpediatricpatientswithependymoma
AT hoeltgenline epen15radiotherapywithheliumionshasthepotentialtoimprovebothendocrineandneurocognitiveoutcomeinpediatricpatientswithependymoma
AT debusjurgen epen15radiotherapywithheliumionshasthepotentialtoimprovebothendocrineandneurocognitiveoutcomeinpediatricpatientswithependymoma
AT herfarthklaus epen15radiotherapywithheliumionshasthepotentialtoimprovebothendocrineandneurocognitiveoutcomeinpediatricpatientswithependymoma
AT harrabisemi epen15radiotherapywithheliumionshasthepotentialtoimprovebothendocrineandneurocognitiveoutcomeinpediatricpatientswithependymoma